Market Overview

PeptiDream Announces Collaboration, License Agreement with Lilly

Share:

PeptiDream
(PeptiDream)(TOKYO:4587), announced that they have entered into a
Collaboration and License Agreement with US-based Eli Lilly and Company
(Lilly)(NYSE: LLY) on 19 December 2013. Under the agreement, PeptiDream
will identify macrocyclic peptides as potential drug candidates for
disease targets being pursued by Lilly. PeptiDream will leverage its
proprietary Peptide Discovery Platform System (PDPS) technology for
translational synthesis, selection, and screening of nonstandard
macrocyclic peptides, and Lilly will be responsible for any subsequent
research and development as pharmaceutical candidates.

Under the terms of the Agreement, PeptiDream will receive an undisclosed
upfront payment, research funding and milestone payments upon the
successful achievement of certain development milestones.

See full press release

Posted-In: News Contracts Management Global

 

Related Articles (LLY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed

Xerox Acquires Invoco; Terms Not Disclosed